Cargando…

Practical limitations of monocyte subset repartitioning by multiparametric flow cytometry in chronic myelomonocytic leukemia

Detalles Bibliográficos
Autores principales:	Pophali, Prateek A., Timm, Michael M., Mangaonkar, Abhishek A., Shi, Min, Reichard, Kaaren, Tefferi, Ayalew, Pavelko, Kevin, Villasboas, Jose C., Jevremovic, Dragan, Patnaik, Mrinal M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697701/ https://www.ncbi.nlm.nih.gov/pubmed/31420531 http://dx.doi.org/10.1038/s41408-019-0231-7

Ejemplares similares

The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukaemia
por: Murali, Aarya, et al.
Publicado: (2021)

Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia
por: Pophali, Prateek, et al.
Publicado: (2020)

Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis
por: Patnaik, M M, et al.
Publicado: (2017)

Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia
por: Patnaik, M M, et al.
Publicado: (2016)

EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental
por: Patnaik, Mrinal M., et al.
Publicado: (2018)

CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes
por: Bezerra, Evandro D., et al.
Publicado: (2021)

How I diagnose and treat chronic myelomonocytic leukemia
por: Patnaik, Mrinal M.
Publicado: (2022)

Blast Phase Chronic Myelomonocytic Leukemia: Mayo-MDACC Collaborative study of 171 cases
por: Patnaik, Mrinal M., et al.
Publicado: (2018)

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
por: Mangaonkar, Abhishek A., et al.
Publicado: (2022)

World Health Organization class-independent risk categorization in mastocytosis
por: Pardanani, Animesh, et al.
Publicado: (2019)

Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies
por: Kourelis, Taxiarchis V., et al.
Publicado: (2019)

Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms
por: Lasho, Terra L., et al.
Publicado: (2018)

Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms
por: Patnaik, Mrinal M., et al.
Publicado: (2018)

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
por: Ilyas, Rimal, et al.
Publicado: (2023)

P709: H2AK119UB IN THE TRANSCRIPTIONAL REGULATION OF PATIENTS WITH ASXL1-MUTANT CHRONIC MYELOMONOCYTIC LEUKEMIA
por: Binder, Moritz, et al.
Publicado: (2023)

Myeloid/lymphoid neoplasm with eosinophilia and rearrangement of PDGFRA presenting as myeloid sarcoma
por: Barouqa, Mohammad, et al.
Publicado: (2022)

Repartition of the cycles in 1994
por: Boillot, J, et al.
Publicado: (1994)

Mast cell sarcoma: 2 Mayo Clinic cases
por: Singh, Amritpal, et al.
Publicado: (2022)

Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases
por: Reichard, Kaaren K., et al.
Publicado: (2022)

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival
por: Abdelmagid, Maymona G., et al.
Publicado: (2023)

Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome
por: Al-Kali, Aref, et al.
Publicado: (2023)

Monocyte subsets to differentiate chronic myelomonocytic leukemia from reactive monocytosis
por: Hwang, Sang Mee, et al.
Publicado: (2020)

Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms
por: Alkhateeb, Hassan B., et al.
Publicado: (2022)

P734: CLONAL HEIRARCHY AND HETEROGENEITY IN STAG2M MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE
por: Katamesh, Bahga, et al.
Publicado: (2023)

ASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26
por: Perez Botero, J, et al.
Publicado: (2015)

P747: CLINICAL CHARACTERISTICS AND OUTCOME OF EZH2-MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE
por: Oum, Muhamad, et al.
Publicado: (2023)

Evaluation by Flow Cytometry of Mature Monocyte Subpopulations for the Diagnosis and Follow-Up of Chronic Myelomonocytic Leukemia
por: Picot, Tiphanie, et al.
Publicado: (2018)

P722: CHARACTERISATION OF PHF6 MUTATIONS IN MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE
por: Sai Mittapalli, Amrutha, et al.
Publicado: (2023)

P1323: PREDICTION OF NON-RELAPSE MORTALITY BY EASIX AND HCT-CI SCORES IN PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA UNDERGOING ALLOGENEIC STEM CELL TRANSPLANT
por: Baranwal, A., et al.
Publicado: (2022)

Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia
por: Patnaik, M M, et al.
Publicado: (2016)

Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance
por: Patnaik, M M, et al.
Publicado: (2016)

1988 LPI beam studies: Repartition and responsibility
Publicado: (1987)

SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity
por: Mangaonkar, Abhishek A., et al.
Publicado: (2022)

Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia
por: Binder, Moritz, et al.
Publicado: (2022)

Mapping Cell Phenomics with Multiparametric Flow Cytometry Assays
por: Liu, Yang, et al.
Publicado: (2022)

Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders
por: Ferrer, Alejandro, et al.
Publicado: (2022)

Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study
por: Xie, Zhuoer, et al.
Publicado: (2021)

Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
por: Gangat, Naseema, et al.
Publicado: (2022)

P1346: THE IMPACT OF CYTOTOXIC THERAPY ON THE RISK OF PROGRESSION AND DEATH IN PATIENTS WITH CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE.
por: Marissa, LI, et al.
Publicado: (2023)

Correction to: Hybridization capture-based next-generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis
por: He, Rong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_a6kguildi38g2l9boc31ljphtf